Clinical trials of antihypertensive drugs typically last up to 5 years, but lifelong therapy for patients with hypertension is recommended in all treatment guidelines. To address this discrepancy, investigators from the Systolic Hypertension in the Elderly Program have published data from a 22-year follow-up showing sustained benefits of antihypertensive treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265, 3255–3264 (1991).
Sutton-Tyrrell, K., Wildman, R., Newman, A. & Kuller, L. H. Extent of cardiovascular risk reduction associated with treatment of isolated systolic hypertension. Arch. Intern. Med. 163, 2728–2731 (2003).
Kostis J. B. et al. Association between chlorthalidone treatment of systolic hypertension and long-term survival. JAMA 306, 2588–2593 (2011).
Staessen, J. A. et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J. Hypertens. 22, 847–857 (2004).
Beckett, N. et al. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ 344, d7541 (2011).
Holman, R. R., Paul, S. K., Bethel, M. A., Neil, H. A. & Matthews, D. R. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N. Engl. J. Med. 359, 1565–1576 (2008).
Multiple Risk Factor Intervention Trial Research Group. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation 82, 1616–1628 (1990).
Bosch, J. et al. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 112, 1339–1346 (2005).
Sytkowski, P. A., D'Agostino, R., Belanger, A. & Kannel, W. B. Secular trends in long-term sustained hypertension, long-term treatment and cardiovascular mortality. The Framingham Heart Study 1950 to 1990. Circulation 93, 697–703 (1996).
Mancia, G. Antihypertensives in octogenarians. BMJ 344, d7293 (2012).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Mancia, G. Does antihypertensive treatment have long-term benefits?. Nat Rev Cardiol 9, 130–132 (2012). https://doi.org/10.1038/nrcardio.2012.11
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2012.11
